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Abstract
TGF-b is widely held to be critical for the maintenance and function of regulatory T (Treg) cells and thus peripheral tolerance.
This is highlighted by constitutive ablation of TGF-b receptor (TR) during thymic development in mice, which leads to a
lethal autoimmune syndrome. Here we describe that TGF-b–driven peripheral tolerance is not regulated by TGF-b signalling
on mature CD4+ T cells. Inducible TR2 ablation specifically on CD4+ T cells did not result in a lethal autoinflammation.
Transfer of these TR2-deficient CD4+ T cells to lymphopenic recipients resulted in colitis, but not overt autoimmunity. In
contrast, thymic ablation of TR2 in combination with lymphopenia led to lethal multi-organ inflammation. Interestingly,
deletion of TR2 on mature CD4+ T cells does not result in the collapse of the Treg cell population as observed in constitutive
models. Instead, a pronounced enlargement of both regulatory and effector memory T cell pools was observed. This
expansion is cell-intrinsic and seems to be caused by increased T cell receptor sensitivity independently of common gamma
chain-dependent cytokine signals. The expression of Foxp3 and other regulatory T cells markers was not dependent on TGF-
b signalling and the TR2–deficient Treg cells retained their suppressive function both in vitro and in vivo. In summary,
absence of TGF-b signalling on mature CD4+ T cells is not responsible for breakdown of peripheral tolerance, but rather
controls homeostasis of mature T cells in adult mice.
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Introduction
Transforming growth factor b (TGF-b1) is a cytokine that is
expressed throughout the hematopoietic system. It was initially
described to suppress T cell proliferation [1], but later found to
also support differentiation of T cells into specialized subsets. Mice
deficient in TGF-b1 show hyperactivation and uncontrolled
expansion of T cells leading to a lethal multi-organ autoimmune
disorder [2]. Likewise, deficiency of either subunit of the
heterodimeric TGF-b receptor (TR) is lethal [3,4]. T-cell–specific
expression of a dominant-negative receptor mutant (DN-TR2)
under the CD4 promoter results in a lymphoproliferative disease
with infiltrates to multiple organs and development of severe
inflammatory bowel disease [5]. Similar mice that express a DN-
TR2 construct under human CD2 promoter presented with
disease symptoms at the age of 3–4 mo [6]. The lymphoprolifer-
ative disease in these mice is caused primarily by expansion of
CD8+ T cells that even progress to leukaemia [7,8]. Genetic
ablation of TR2 in hematopoietic or, more specifically, in T cells
leads to lymphadenopathy, splenomegaly, and inflammation of
various organs followed by death at 3 wk of age [9–11]. Thus, all
these models of interrupted TR function suggest an essential,
nonredundant role for TGF-b1 in the maintenance of T cell
tolerance. The observed autoimmune syndrome was initially
thought to be caused by the apparent loss of regulatory T (Treg)
cells. Particularly thymic Treg development and survival seem to
require TGF-b signals [10–12]. Yet neither reconstitution with
WT Treg cells nor mixed bone marrow chimera experiments
resulted in an amelioration of the autoimmune phenotype in
these models [10,11]. Notwithstanding that cell type and reason
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for T-cell–mediated autoimmunity in the absence of TGF-b
signalling remain unclear, in all these models thymic development
was found to be altered [11–14]. A recent study shows that
deletion of TR2 in mature T cells by dLck-Cre does not cause a
fatal autoimmune syndrome [15]. In this model, however, the role
of TGF-b signalling in mature Treg cells could not be addressed,
since dLck-Cre did not lead to deletion of TR2 in Foxp3+ CD4+ T
cells. Thus, our current, unbiased knowledge about the in vivo role
of TGF-b for peripheral T, especially Treg, cells appears to be
incomplete. To overcome this and analyze TGF-b function in T
helper and Treg cells independent of developmental defects as well
as systemic autoimmunity, we inducibly abrogated TGF-b
signalling in peripheral CD4+ T cells. Surprisingly, loss of TR2
function in mature T cells, including Treg cells, did not lead to the
spontaneous development of autoimmunity. Adoptive transfer of
TR2-deficient CD4+ T cells into lymphopenic hosts led only to
colitis but not systemic disease. However, the induced TR2
deletion in thymocytes of lymphopenic mice resulted in a rapidly
developing lethal auto-inflammatory disorder. When TR2 abla-
tion was restricted to postthymic T cells, we observed that not only
Tem (CD62L
loCD44hi) cells but also Treg cells exhibited hyper-
proliferation resulting from increased sensitivity to TCR signalling.
TR2-deficient Treg cells retained their suppressive capacity both in
vitro and in vivo. For mature CD4+ T cells in the adult mouse, TGF-
b seems therefore to solely be a regulator of Treg as well as Tem cell
expansion but is not required for the maintenance of tolerance.
Results
Induced Ablation of TR2 From Peripheral CD4+ T Cells
Previous genetic studies of the function of TGF-b1 in T cells
have either relied on germline gene deficiencies or involved cell-
type–specific mutagenesis. Consequently, these models were
biased by strong alterations in thymic development [10–13]. To
specifically address the role of TGF-b signalling in mature CD4+ T
cells, we circumvented any developmental impact through the
generation and use of a new tamoxifen-inducible [16] CD4-
CreERt2 knock-in strain (Figure S1A,B). We first tested the
tamoxifen-induced recombination of this strain with the help of
two fluorescent reporter mouse strains (RAGE and ROSA-EYFP)
and found efficient and specific recombination in CD4+ T cells
(unpublished data). As anticipated, recombination also took place
in a small fraction of CD4+ splenic dendritic cells (DCs) and innate
lymphoid cells (unpublished data). Since removal of the neomycin
resistance gene (Neo(R)) by FLP-mediated deletion [17] reduced
recombination efficiency without gain of specificity, a phenome-
non observed before [18], we used animals bearing the Neo(R)-
containing allele for all further experiments. To investigate the role
of TGF-b signalling in peripheral T helper cells, we crossed the
CD4-CreERt2 with a conditional TR2 allele (TR2f) [9] obtaining
CD4-CreERt2/TR2f/f (hereafter called iCD4TR2) experimental
mice as well as CD4-CreERt2/TR2f/+ and TR2f/f control mice.
First, we tested ablation of TR2 in CD4+ T cells 14 d after
commencing 5 d of tamoxifen treatment of iCD4TR2 mice
(hereafter called tam-iCD4TR2 mice). mRNA levels within sorted
naı¨ve, central memory, effector memory/effector (Tem) and
regulatory (Treg) CD4
+ T cells from tam-iCD4TR2 mice indicated
a recombination frequency of 90%–95% in mature T cells
(Figure 1A), placing it at similar efficiency as many constitutive
Cre strains [10,11]. Equally high deletion efficiencies were
observed in CD4+ T cells from mesenteric LN (mLN) and the
lamina propria (LP) (Figure 1B). Surface expression analysis of
TR2 on blood and spleen CD4+ T cells supported this observation
(Figure 1C, Figure S2A, and unpublished data) and also showed
that expression of TR2 by other cell types including CD8+ T cells
was unaffected (Figure 1C and Figure S2A). As expected, TGF-b–
induced phosphorylation of Smad2 [19] was virtually absent in
CD4+ T cells from tam-iCD4TR2 mice 2 wk p.a. (Figure 1D). We
thus conclude that target allele recombination in our inducible
system is specific and efficient.
Because CD4-Cre-mediated TR2-ablation resulted in a strong
thymic phenotype including reduction of single positive CD8+ T
cells, abrogation of NK T cell development, and enhanced
negative selection [11,12], we investigated the extent and
consequences of induced TR2 ablation in the thymus. Two weeks
p.a. the surface expression of TR2 was reduced only slightly on
CD4+ thymocytes but not on any of the other major thymocyte
compartments (Figure 1E). Reduction of TR2 mRNA levels was
found not only in CD4+ but also in a small fraction of CD8+ SP
thymocytes only 2 wk p.a., indicating low-level and transient
recombination at the DP stage (Figure S2B). Also, expression of
CD4, CD8, CD5, CD24, CD62L, and CD69 were unchanged in
the thymus (Figure 1F and unpublished data) as were number and
phenotype of thymic Treg cells (Figure 1F). Thus, our model allows
the study of TGF-b signalling in mature CD4+ T cells by pulse-
chase experiments without significantly disturbing thymic T cell
development.
Peripheral Abrogation of TR2 Signalling in CD4+ T Cells
Does Not Lead to Autoimmunity
Constitutive ablation of TGF-b signalling during thymic
development of abT cells (CD4-Cre or Lck-Cre–mediated) but
not during peripheral life (dLck-Cre–mediated) invariably results
in a generalised and rapidly lethal autoimmune disorder
[10,11,14,15]. When we followed tam-iCD4TR2 mice after
induction of receptor deletion, they appeared healthy and showed
no weight loss 2 and 4 wk after 5 d of tamoxifen treatment and up
to 3 mo after feeding with tamoxifen citrate for 2 mo (Figure 2A).
Because mild autoimmunity may not present clinically, we
performed histopathological analysis of liver, kidney, pancreas,
heart, colon, and thyroid gland but could not detect cellular
infiltrates in any of these organs (unpublished data). We also tested
for secondary dysregulation of B cell tolerance manifested by
autoantibody production, as previously described upon thymic
deletion of TR2 expression [11]. Yet sera from tam-iCD4TR2
mice at 6 wk or even 5 mo p.a. did not contain significant levels of
Author Summary
TGF-b is a cytokine thought to be critical for the
maintenance and function of tolerance in the immune
system. In many studies the disruption of TGF-b signalling in
CD4+ T cells (a type of white blood cell that coordinates
immune responses) has resulted in autoimmune syn-
dromes. We show here that the induced removal of this
cytokine’s receptor from these specialised blood cells results
in an astonishingly mild outcome. Contrary to expectations,
the number of regulatory T cells is actually increased, and
we find that these cells are not dependent on TGF-b
signalling. We also show that removal of the receptor from
mature CD4+ T cells does not lead to lethal autoinflamma-
tion; only when we removed the receptor during develop-
ment of the cells did we see the characteristic lethal
multi-organ inflammation reported previously in constitu-
tive models of TGF-b receptor ablation. In summary, our
findings indicate that although TGF-b regulates mainte-
nance of mature CD4+ T cells, its signals are dispensable for
immune tolerance within this cell population.
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autoantibodies as shown by ELISA against dsDNA (Figure 2B).
Thus, removal of TR2 from mature CD4+ T cells does not result
in tolerance loss or autoimmunity. To exclude that recent thymic
emigrants could dilute out cells lacking TR2, we thymectomized
mice 1 wk before an 8-wk tamoxifen citrate treatment. Again, we
failed to observe any signs of autoimmune disease by clinical
appearance and weight loss up to 5 mo p.a. (Figure 2C) even
though the frequency of TR2-deficient cells remained constant
until the end of the experiment (Figure 2D). The absence of
elevated serum antibody levels, autoantibodies, and organ
infiltrates again excluded subclinical tolerance loss (Figure 2E,F
and unpublished data). Furthermore, CD8low or CD4+ NK1.1+ T
cells, proposed to carry autoreactive activity in the constitutive
TR2-deficient models [10], were not detected 2 and 4 wk as well
as 5 mo p.a. and after thymectomy (Figure 2G and unpublished
data). In conclusion, in contrast to models of constitutively
impaired TGF-b signalling in T cells [5,6,10,11], induced TR2
ablation from peripheral CD4+ T cells does not result in the loss of
self-tolerance.
Induced Ablation of TR2 During Thymic Development
Combined with Lymphopenia Results in Lethal
Autoimmunity
Abrogation of TGF-b signalling through CD4-Cre takes place
during thymic development and affects all abT cells including Treg
Figure 1. Validation of CD4-CreERt2/tamoxifen-mediated TR2 ablation. (A) Quantitative RT-PCR of TR2 mRNA in FACS-sorted splenic CD4+ T
cell subsets. These data are representative results of three independent experiments. (B) Quantitative RT-PCR of TR2 mRNA in FACS-sorted CD4+ T
cells from mesenteric lymph nodes and lamina propria. These data are representative results of three independent experiments. (C) Flow cytometric
analysis of TR2 expression by CD4+ and CD8+ T cells from peripheral blood. These data are representative results of four independent experiments.
(D) Western blot analysis of pSmad2 and Vinculin in lysates of magnetically purified splenic CD4+ T cells from tam-iCD4TR2 and control mice 2 wk
p.a.. The cells were cultured for 40 min in the presence of antiCD3/CD28 either with or without 20 ng/ml TGFb-1. These are representative data of
two independent experiments. (E) Flow cytometric analysis of TR2 expression by thymocytes 2 wk p.a. These data are representative results of two
independent experiments. (F) Flow cytometric analysis of expression of CD4 and CD8 by thymocytes (left panel) as well as Foxp3 and CD25 by CD4+
SP thymocytes (right panel) from tam-iCD4TR2 and control mice at 2 wk p.a. These data are representative results of three independent experiments.
doi:10.1371/journal.pbio.1001674.g001
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cells. This thymic TR deletion results in lethal autoimmunity, in
contrast to peripheral TR deletion through CD4-CreERt2. To
understand the underlying cause of the different outcomes of TR2
ablation in T cells, we assessed whether they were caused by
deletion frequency, by ablation during thymic development, or by
lymphopenia. To mimic the environment found in neonates with
constitutive T-cell–specific TR2 ablation [10,11], we induced
recombination during thymic development in a lymphopenic
environment: We initiated treatment with tamoxifen of Rag-12/2
mice 3 d before irradiation and reconstitution with bone marrow
of iCD4TR2 or control mice (experimental scheme outlined in
Figure S3A). Tamoxifen treatment led to deletion of TR2 in the
thymus of mice reconstituted with iCD4TR2 bone marrow: both
CD4+ and CD8+ T cells lacked TR2 expression (Figure 3A). The
mice developed signs of sickness 28 d after bone marrow
reconstitution (apathy, runted appearance, weight loss) and started
dying after 30 d (Figure 3B,C). Mice that received control bone
marrow (CD4-CreERt2/TR2f/+) did not shown any signs of
disease (Figure 3B). Sick bone marrow chimeras presented with T
cell infiltrates only in lung and liver tissue but not the colon
(Figure 3D and unpublished data). The frequency of
CD62LhiCD442 naı¨ve T (Tn) cells was severely reduced and of
CD62LloCD44+ Tem cells highly increased in both CD4
+ and
CD8+ T cell compartments (Figure 3E). As has been reported
Figure 2. Absence of autoimmunity after TR2 ablation in mature CD4+ T cells. (A) iCD4TR2 and control mice were treated with tamoxifen
citrate for 2 mo followed by 3 mo on normal diet and body weight was monitored (mean 6 SEM, 5 mice per group, representative data of two
independent experiments). (B) ELISA for anti-dsDNA antibodies in sera from tam-iCD4TR2 and control mice 2, 4, 6 wk, and 5 month p.a.; as positive
control a serum from a fas-deficient mouse was used. (C) iCD4TR2 and control mice were thymectomised 1 wk before the beginning of tamoxifen
treatment and treated with tamoxifen citrate for 2 mo followed by 3 mo on normal diet and body weight was monitored (mean 6 SEM, 5 mice per
group, representative data of two independent experiments). (D) Flow cytometric analysis of TR2 expression by CD4+ and CD8+ T cells from
peripheral blood after 5 mo postthymectomy and tamoxifen treatment. (E) Analysis of antinuclear antibodies by immunofluorescent staining of
NIH3T3 cells with sera from indicated mice. Representative micrographs are shown. The size bar indicates 40 mm. (F) Representative micrographs of
H&E-stained tissue sections of indicated organs isolated from thymectomised tam-iCD4TR2 or control mice from (C). The size bar indicates 100 mm.
(G) Flow cytometric analysis of NK1.1 expression on splenic CD4+ and CD8+ T cells isolated from tam-iCD4TR2 or control mice 2 wk posttamoxifen
administration. These are representative data of three independent experiments.
doi:10.1371/journal.pbio.1001674.g002
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before in constitutive CD4-Cre–mediated deletion [10,11], we also
observed a significantly decreased number of peripheral Treg cells
(Figure 3F). CD4+CD25high T cells showed similar levels of Foxp3
expression while CTLA-4 was significantly up-regulated
(Figure 3G). When tamoxifen treatment started 5 wk after bone
marrow transfer, we observed no sign of autoimmunity, tissue
infiltration, and only slight Tem expansion (Figure 3H,I, Figure
S3B, and unpublished data), thus excluding the possibility that
bone marrow chimerism per se could predispose to development
of the disease.
The treatment of bone marrow chimeras with tamoxifen from
the onset on led to deletion of TR2 also in CD8+ T cells, indicating
efficient recombination already during the thymic DP stage. To
exclude that these TR2-negative CD8+ T cells were causing
disease, we repeated the experiment described in Figure 3A–G
with deletion of CD8+ T cells (Figure S3C). Experimental
chimeras treated with anti-CD8 antibody developed the lethal
autoimmune syndrome only slightly later than those treated with
isotype control (Figure 3J). Lungs and livers isolated from both
groups of experimental chimeras presented with infiltrates
(Figure 3K and unpublished data). We found no difference in
weight loss, survival, or tissue pathology between control mice
treated with anti-CD8 antibody or isotype control. Also, TR2
deletion was equally efficient in both groups (unpublished data).
Thus, CD4+ T cells are the main effectors of disease upon TR2
ablation during thymic development in a lymphopenic situation.
Taken together, the fact that the TR2 deletion frequency in
CD4+ T cells is similar in all these bone marrow chimerism
experiments suggests that the cause of the autoimmune syndrome
is either the absence of TR2 during thymic development or during
repopulation of a lymphopenic environment, thus mimicking the
observations made in constitutive models of TR2 deletion (i.e.,
CD4-Cre/TR2f/f).
Transfer of TR2-Deficient CD4+ T Cells Into Lymphopenic
Hosts Does Not Lead to Multi-Organ Inflammation But to
Colitis
To distinguish between altered thymic development and
lymphopenia as cause of the autoinflammation, we assessed the
influence that different lymphopenic conditions had on the
behaviour of TR2-deficient CD4+ T cells. To achieve CD4+ T-
cell–restricted lymphopenia, we treated thymectomized animals
with a low dose of anti-CD4 antibody. This treatment led to a
,90% depletion of blood CD4+ T cells (Figure 4A, Figure S4A,
and unpublished data) followed by acquisition of an activated
phenotype by the remaining CD4+ T cells in both control and
experimental mice (Figure 4B). To obtain severe general
lymphopenia we used sublethal irradiation (Figure 4C and Figure
S4B). In this setting both CD4+ and CD8+ T cells acquired the
activated phenotype (unpublished data). Even though in both
acute lymphopenic conditions we observed pronounced lympho-
penia-driven T cell expansion, none of the animals presented with
signs of autoimmune disease by appearance, anti-dsDNA autoan-
tibody titres, and histology until week 20 (unpublished data).
Again, TR2 ablation was similarly efficient throughout these
experiments (Figure S4A). Only when we adoptively transferred
TR2-deficient cells into a completely lymphopenic environment
(RAG-1 deficiency), strong colitis developed within 30 d
(Figure 4D,E and unpublished data), which was accompanied by
a massive infiltration of CD4+ T cells to mesenteric lymph nodes
(Figure S4C). Interestingly, the mice presented with neither apathy
nor runted appearance, and histology did not reveal any
inflammation of lungs or livers, which is a characteristic feature
in mice in which TGF-b signalling is abrogated in thymocytes
(Figure 4E and unpublished data). Thus, adoptive transfer-
mediated colitis can be induced by TR2-deficient T cells even in
the presence of Treg cells, but a general autoinflammatory
syndrome is not observed. In vivo TR2 deletion in CD4+ T cells
combined with acute lymphopenia, however, does not lead to loss
of tolerance.
Dysregulated Effector CD4+ T Cell Homeostasis in
Absence of TGF-b Signalling
To better understand the role of TGF-b signalling in mature
CD4+ T cells, we analysed T effector homeostasis after TR2
removal in a longitudinal manner. We found slightly reduced
CD4+ T cell numbers in spleen and LNs 2 and 4 wk p.a.
(Figure 5A and unpublished data) while the total number of CD8+
and of central memory CD4+ T (CD62lhiCD44+) cells remained
unchanged (unpublished data). In addition, we observed a modest
but significant expansion of Tem cells. This phenotype was
transient as cell numbers and the frequency of Tem cells returned
to normal 6 wk p.a. (Figure 5B and unpublished data). In support
of this observation, BrdU incorporation revealed increased
proliferation of Tem but not of Tn and central memory CD4
+ T
cells 2 wk p.a. (Figure 5C and unpublished data). To test whether
the increase of Tem cells was transient due to replacement by new
TR2-expressing T cells, we thymectomized mice prior to TR2
ablation. In the absence of thymic emigration we observed that the
elevated numbers of Tem cells persisted (Figure 5D).
To investigate whether the activation and proliferation of Tem
cells upon TR2 ablation was a cell-intrinsic property or driven in
trans by cell extrinsic factors, we generated bone marrow chimeras
by mixing WT CD45.1+ and either iCD4TR2 CD45.2+ or control
Figure 3. Development of lethal autoimmunity after thymic deletion of TR2. Tamoxifen-treatment of Rag12/2 mice started 3 d before
reconstitution with T-cell–depleted bone marrow from iCD4TR2 or control mice (A–G). (A) Flow cytometric analysis of TR2 expression by CD4+ and
CD8+ T cells at day 34. Representative data of two independent experiments. (B) Body weight was monitored during the whole experiment (mean 6
SEM, 5 mice per group, representative data of two independent experiments). (C) Kaplan-Meyer survival graph for all animals of experiments. (D)
Representative micrographs of H&E- and anti-CD3-stained tissue sections of indicated organs at day 34. The size bar indicates 100 mm. (E) Flow
cytometric analysis of the expression of CD44 and CD62l by CD4+ and CD8+ T cells. The percentage of Tn and Tem cells in the spleen of experimental
and control chimeric mice (mean 6 SEM, 6 mice per group, analysed in two independent experiments). (F) Percentage and number of splenic Treg
cells at day 34 (mean 6 SEM, 5 mice per group; representative data of two independent experiments). (G) Flow cytometric analysis of FoxP3 and
CTLA-4 by indicated splenic CD4+ T cells subsets at day 34 (representative data of three independent experiments). Mean florescence intensity of
CTLA-4 expression by splenic Treg cells (right panel, mean 6 SEM, 4 mice per group; representative data of three independent experiments). (H)
Rag12/2 mice were reconstituted with T-cell–depleted bone marrow from iCD4TR2 or control mice. Tamoxifen treatment of recipients started 5 wk
postreconstitution and body weight was monitored during the whole experiment (mean 6 SEM, 5 mice per group; representative data of two
independent experiments). (I) The percentage of Tem, cells in the spleen of experimental and control chimeric mice (mean 6 SEM, 6 mice per group,
analysed in two independent experiments). (J) Tamoxifen-treatment of Rag12/2 mice started 3 d before reconstitution with T-cell–depleted bone
marrow from iCD4TR2 or control mice. At day 15 posttransfer treatment with anti-CD8 antibody or isotype control started. Shown is a Kaplan-Meyer
survival graph for all animals in the experiments (representative data of two independent experiments). (K) Representative micrographs of H&E-
stained lung sections in the terminal stage of the disease. The size bar indicates 100 mm.
doi:10.1371/journal.pbio.1001674.g003
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TR2f/f CD45.2+ bone marrow (scheme depicted in Figure 5E). In
chimeras containing iCD4TR2 bone marrow, the frequency of
mutant CD4+ T cells was increased significantly at 4 wk p.a.
(unpublished data). Two weeks p.a. activation of CD4+ T cells and
Tem cell proliferation were restricted to cells lacking TR2
(Figure 5F). The TR2-deficient Tn cell compartment was
diminished while the mutant central memory compartment was
unchanged (unpublished data). Analysis of control chimeras
showed no differences between the CD45.1+ and CD45.2+
populations. These data thus suggest that TR2 regulates the
homeostasis of mature Tem and Tn cells. While in models of
constitutive TR2 ablation a large fraction of CD4+ T cells
developed into IFN-c–producing Th1 cells [11], we found only
slightly increased IFN-c production but no difference in T-bet
levels after peripheral deletion of TR2 (Figure 5G). Production of
Th2 cytokines was hardly detectable (Figure 5G) and the
expression of the chemokine receptors CCR4, CCR5, CCR6,
and CCR7 was unchanged (unpublished data).
Thus, hyperactivation, increased proliferation of Tem cells, and
the reduction of the Tn cell compartment are cell-intrinsic
consequences of TR2 ablation. The postthymic abrogation of
TGF-b signalling does not lead to spontaneous acquisition of a
Th1 phenotype.
Increased TCR-Dependent Activation in Absence of TR2
Since the up-regulation of CD69 upon TR2 ablation (Figure 6A)
supported the idea of a TCR-dependent effect [20] of TR2
signalling on proliferation rate of mature CD4+ T cells in vivo, we
Figure 4. TR2-deficiency in CD4+ T cells in combination with severe lymphopenia leads to colitis. (A) iCD4TR2 and control mice were
thymectomised at the age of 7 wk, 1 wk before tamoxifen treatment started, and treated once (day 0) with anti-CD4 antibody. Body weight was
monitored during whole period of experiment (mean 6 SEM, 4 mice per group). (B) Flow cytometric analysis of CD44 and CD62l expression by
splenic CD4+ and CD8+ T cells isolated at day 90 (experiment as in A). (C) iCD4TR2 and control mice were irradiated (550 rad) 5 d after starting
tamoxifen treatment. Tamoxifen treatment was continued for 90 d. Body weight was monitored during the whole period of experiment (mean 6
SEM, 4 mice per group). (D) Purified T cells isolated from tam-iCD4TR2 and control mice 2 wk p.a. were transferred to Rag2/2 mice. Body weight was
monitored during the whole period of the experiment (mean 6 SEM, 5 mice per group). (E) Representative micrographs of H&E-stained tissue
sections of indicated organs isolated from Rag2/2 mice 7 wk after adoptive transfer of T cells. The size bar indicates 200 mm.
doi:10.1371/journal.pbio.1001674.g004
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hypothesized that TR2 alters either the sensitivity to TCR ligands
or the signalling through homeostatic cytokine receptors. First we
assessed whether the absence of TR2 would result in increased
sensitivity to TCR triggering. We stimulated CD4+ T cells in the
presence of titrated amounts of anti-CD3 antibody and found an
increased response to TCR stimulation through suboptimal anti-
CD3 concentrations (Figure 6B), indicating an increased sensi-
tivity to TCR stimulation after deletion of TR2. To exclude the
possibility that this was the result of a larger fraction of
experienced CD44hi cells within the pool of stimulated TR2-
deficient cells, we activated naı¨ve and effector memory cells
separately. Again the TR2-deficient cells, naive and experienced,
presented with higher sensitivity to TCR stimulation (Figure
S5A).
Indo-1–based ratiometric analysis revealed a small but signif-
icant increase in steady-state cytoplasmic calcium concentrations
(Figure 6C). Upon stimulation the calcium influx was accelerated,
suggesting an increased sensitivity of TR2-deficient T cells
(Figure 6C). We did not find, however, differences in phosphor-
ylation of CD3f, SLP76, lck, ZAP70, or ERK upon TCR
stimulation (unpublished data). While no differences in CD25
expression or IL-2 production were found (Figure 6D), a slight
increase of CD122 (IL-2Rb) on CD4+ tam-iCD4TR2 T cells was
detected 2 wk p.a. (Figure 6D). This could potentially have led to
Figure 5. Increased proliferation of Tem cells upon removal of TR2. (A) Absolute number of CD4
+ T cells in spleens of tam-iCD4TR2 and
control mice 1, 2, 4, and 6 wk p.a. Mice were treated with tamoxifen for 5 consecutive days (mean 6 SEM, 9 mice per group, analysed in three
independent experiments). (B) Percentage of Tem, cells in the spleen of tam-iCD4TR2, and control mice at indicated time points (percentage out of
CD4+ T cell, mean 6 SEM, 9 mice per group, analysed in three independent experiments). (C) The percentages of BrdU+ Tem cells isolated from
spleens of tam-iCD4TR2 and control mice, gated on CD4+ T cells (mean 6 SEM, 9 mice per group, analysed in three independent experiments). (D)
The percentage of Tn and Tem cells in the spleen of thymectomised tam-iCD4TR2 and control mice at indicated time points (mean 6 SEM, 9 mice per
group, analysed in two independent experiments). (E) Rag12/2 mice were reconstituted with T-cell–depleted bone marrow from WT CD45.1+ and
CD45.2+ iCD4TR2 or TR2 mice in 1:1 ratio and treated with tamoxifen for 5 consecutive days 5 wk postreconstitution. Scheme of the experimental
setup. (F) The percentage of CD4+ Tem of total CD4
+ T cells from LNs are shown (left panel) and the percentage of BrdU+ Tem cells isolated from LNs
(right panel) (mean 6 SEM, 10 mice per group, analysed in three independent experiments). (G) Flow cytometric analysis of the expression of IFN-c
and IL-4 by splenic CD4+ T cells from tam-iCD4TR2 and control mice 2 wk p.a. (representative data of two independent experiments). Quantitative RT-
PCR of T-bet mRNA in sorted splenic CD4+ T cell. These data are representative results of two independent experiments (right panel).
doi:10.1371/journal.pbio.1001674.g005
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altered sensitivities to IL-15 or IL-2. However, the hyperprolifera-
tion of TR2-deficient T cells stimulated by suboptimal TCR
activation could not be corrected by blockade of the IL-2R
(Figure 6E and Figure S5B). Likewise, dose responses to IL-2 and
IL-15 were equal in TR2+ and TR22 CD4+ T cells (Figure 6F and
Figure S5B). Furthermore, reactivity to IL-7 was unchanged in this
in vitro assay (unpublished data). Thus, the hyperproliferative
activity of TR2-deficient CD4+ T cells appears to be the result of
increased TCR sensitivity but not of cytokine-mediated signals. To
rule out that increased survival of TR2-deficient cells was
contributing to the observed expansion, we removed the receptor
from splenic CD4+ T cells in vitro and assessed survival. The result
was an increased incidence of apoptosis by cells lacking TR2 as
shown by Annexin V staining after 20 and 45 h (Figure S5C), thus
excluding this possibility.
Dysregulated Homeostasis of Regulatory T Cells After
Ablation of TR2
Treg cell development and maintenance is generally thought to
be critically dependent on TGF-b signals [21,22] as thymic
deletion of TGF-b signalling was shown to result in a strong
reduction of Treg cell number in the periphery [10,11,14]. When
we examined Treg cell homeostasis after peripheral ablation of
TR2 from CD4+ T cells, we made the surprising observation of
increased frequency and number of Treg cells 2 and 4 wk p.a. as a
result of hyperproliferation (Figure 7A and unpublished data). This
increase in the Treg population size was also observed in various
LNs, the spleen, the lung, Peyer’s patches, but not in the intestinal
lamina propria (Figure 7B and unpublished data) and was stable in
thymectomized animals (Figure 7C and unpublished data). Mixed
bone marrow chimeras showed that similar to Tem cells, increased
proliferation is an intrinsic property of the TGF-b unresponsive
Treg cells (Figure 7D,E and Figure S6A,B). The majority of the
expanded splenic and LN Foxp3+ Treg cells in tam-iCD4TR2
mice expressed Nrp-1 and Helios (Figure 7F, Figure S6C, and
unpublished data), which suggests a thymic origin [23]. Prolifer-
ation of TR-2–deficient Nrp-1+ regulatory T cells was increased
compared to WT Treg cells (Figure 7G). In thymic Treg precursors
lacking TGF-b signalling, a decrease in the levels of the key
transcription factor FoxP3 [24–26] had been reported [27]. We
did not observe such reduced Foxp3 levels in CD4+CD25+ cells in
short- and long-term experiments (unpublished data) and in the
mixed bone marrow chimeras (Figure 7H). Also, the expression of
key surface molecules by TR2-deficient Treg cells—namely CTLA-
4, GITR (Tnfrsf18), [28,29] and ICOS [30]—remained un-
changed (Figure 7H) in contrast to our observations in the bone
marrow chimera model presenting with a lethal autoinflammatory
syndrome. We found, however, that as described for TR2-negative
Tem also Treg cells presented with an up-regulation of CD69
(Figure S6D). Therefore, to investigate TCR hyperresponsiveness,
splenocytes isolated from tam-iCD4TR2 and control mice 2 wk
p.a. were CFSE-labelled and stimulated with different concentra-
tions of anti-CD3 antibody. Increased proliferation of TR2-
negative Treg cells was observed after 3 d of culture with
Figure 6. Deregulated proliferation control upon removal of TR2. (A) Flow cytometric analysis of CD69 expression by CD4+ splenic T cells
isolated 2 wk p.a. These data are representative results of three independent experiments. (B) Analysis of sensitivity to activation through
measurement of proliferation. Sorted CD4+ T cells were cultured for 72 h and stimulated with different anti-CD3 concentrations. Thymidine was
added for the last 24 h of culture (mean 6 SEM, 4 mice per group, analysed in two independent experiments). (C) Flow cytometric analysis of
cytoplasmic calcium by ratiometric measurement of Indo-1–labelled cells from tam-iCD4TR2 and control mice. TCR crosslinking was performed after
15 s. On the left mean ratio of the baseline (representative data of two independent experiments). (D) Flow cytometric analysis of IL-2, CD25, and
CD122 expression by splenic CD4+ T cells isolated from tam-iCD4TR2 and control mice. These data are representative results of two independent
experiments. (E and F) Proliferation analysis of sorted CD4+ T cells cultured for 72 h with anti-CD3 (0.6 mg/ml) and anti-CD25 (PC61) (E) or indicated
cytokines (F). Thymidine was added for the last 24 h of culture (mean 6 SEM, 4 mice per group, analysed in two independent experiments).
doi:10.1371/journal.pbio.1001674.g006
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Figure 7. Increased proliferation of regulatory T cells upon removal of TR2. (A) The percentage of Treg cells (left panel) and number of Treg
cells (right panel) in the spleen of tam-iCD4TR2 and control mice at indicated time points (mean 6 SEM, 9 mice per group, analysed in two
independent experiments). (B) The percentage of Treg cells in the indicated organs of tam-iCD4TR2 and control mice (mean6 SEM, 5 mice per group,
analysed in two independent experiments). (C) The percentage of Treg cells in the spleens of thymectomised tam-iCD4TR2 and control mice 20 wk
p.a. (mean 6 SEM, 9 mice per group, analysed in two independent experiments). (D) The percentage of Treg (left panel) and absolute number of Treg
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suboptimal anti-CD3 concentrations (Figure S6E). Similarly,
sorted Treg cells showed hyperproliferation to anti-CD3–mediated
stimulation when cultured alone or in presence of IL-2 (unpub-
lished data). Taken together, TGF-b signalling suppresses overt
Treg cell proliferation but does not seem to be required for
maintenance of the Treg cell phenotype.
TR2 Expression by Treg Cells Is Not Required for Their
Suppressive Capacity
Since peripheral TR2 ablation resulted in loss of cell cycle
control and thus Treg cell expansion, we tested whether these
mutant Treg cells retained functional characteristics identical to
WT Treg cells. In an in vitro suppression assay TR2-deficient Treg
cells and WT Treg cells inhibited the proliferation of conventional
T cells to a similar extent (Figure 8A,B). This observation was
confirmed in vivo by the capacity of TR2-deficient T cells to
suppress the development of colitis. TR2-deficient or control Treg
cells were co-transferred with CD4+ Tn cells into lymphopenic
RAG1-deficient recipients. While transfer of Tn cells alone
resulted in severe weight loss, indicative of colitis, the disease
was similarly suppressed by co-transfer of Treg cells from tam-
iCD4TR2 or control animals (Figure 8C). Colon histopathology
did not reveal any difference between mice that received TR2-
deficient or WT Treg cells (Figure 8D).
Given that T-cell–mediated autoimmunity upon thymic abla-
tion of TGF-b signalling could not be suppressed by WT Treg cells
[11], we tested whether WT and TR2-deficient Treg could
suppress mutant responder T cells. In the in vitro as well as the in
vivo suppression assay, TR2-deficient T cells remained susceptible
to suppression by Treg cells (WT and mutant) (Figure 8E,F). Taken
together, TGFb is not necessary for the functional capacity of Tregs
to suppress immune responses.
Discussion
The pleiotropic nature of the TGF-b family members has made
it extremely challenging to unravel their function in vivo. All models
of constitutive ablation of TGF-b signalling in abT cells during
thymic development have invariably revealed autoimmune phe-
notypes [5,6,9–11,31–35]. In most of these models [10–12,14] the
Treg cell population collapsed, resulting in almost complete loss of
Treg-mediated peripheral suppression. These observations led to
the dogma that TGF-b1 is required for establishment and
maintenance of T cell tolerance. Yet because gene ablation in
all these systems took place prior to or during thymic development,
it could not be excluded that the observed immune dysregulation
was a consequence of T cell development in the absence of TGF-b
signals. In fact, while Doisne and colleagues showed that NKT
cells depend critically on TGF-b for their development [13],
Ouyang and colleagues reported that even conventional T cell
development is modified by TGF- b signalling [12]. Therefore, to
study the importance of TGF-b for peripheral CD4+ T
lymphocytes, we circumvented such thymus-related abnormalities
cells (right panel) within the LN CD4+ T cells of the indicated CD45.1+ or CD45.2+ bone marrow–derived cells (experiment described in Figure 5E,
mean 6 SEM, 10 mice per group, analysed in three independent experiments). (E) The percentage of BrdU+ Treg cells isolated from LN (experiment
described in Figure 5E, mean6 SEM, 10 mice per group, analysed in three independent experiments). (F) Flow cytometric analysis of Nrp-1 and Foxp3
expression by CD4+ T cells (left panel) and the percentage of Nrp-1+ and Nrp-12 Treg cells within the LN CD4
+ T cells of tam-iCD4TR2 and control mice
2 wk p.a. (right panel) (mean 6 SEM, 9 mice per group, analysed in two independent experiments). (G) Flow cytometric analysis of Ki-67 expression
by Nrp-1+ Treg cells (left panel) and the percentage of Ki-67
+Nrp-1+ Treg cells within the LN CD4
+ T cells of tam-iCD4TR2 and control mice 2 wk p.a.
(right panel) (mean 6 SEM, 9 mice per group, analysed in two independent experiments). (H) Flow cytometric analysis of the expression of CTLA4 by
Treg and Foxp3 by CD4
+CD25+ T cells isolated from spleen of mixed bone marrow chimeras. These data are representative results of three
independent experiments (left panel). Flow cytometric analysis of the expression of ICOS by splenic Treg cells from tam-iCD4TR2 and control mice at
indicated time point p.a. Representative data of three independent experiments.
doi:10.1371/journal.pbio.1001674.g007
Figure 8. Treg cells lacking TR2 are functional. (A) In vitro
suppression assay: sorted conventional CD45.1+CD4+ T cells were
stimulated with anti-CD3 (2 mg/ml) and cocultured with sorted WT Treg
cells or tam-iCD4TR2 Treg cells (isolated 14 d p.a.) at various ratios.
Thymidine was added for the last 24 h of culture. Analysis was
performed after 96 h. Percent suppression as mean 6 SD (analysed in
two independent experiments). (B) In vitro suppression assay: sorted
conventional CD45.1+CD4+ T cells were labelled with CFSE, stimulated
with anti-CD3 (2 mg/ml), and cocultured with sorted wt Treg cells or tam-
iCD4TR2 Treg cells (isolated 14 d p.a.) at various ratios. FACS analysis was
performed after 96 h. These data are representative results of two
independent experiments. (C and D) In vivo suppression assay:
Development of colitis in Rag12/2 mice after transfer of conventional
CD4+ T cells alone or in combination with tam-iCD4TR2 (mice treated
for 5 d, cells isolated 1 wk p.a.) Treg cells or iCD4TR2 Treg cells. Change in
body weight after 8 wk posttransfer (mean, 3 mice per group,
representative data of two independent experiments). (D) Representa-
tive micrographs of H&E-stained small intestine sections from in vivo
suppression experiments isolated from Rag12/2 mice 8 wk after
transfer of the indicated cells. Scoring of colitis severity according to
[60]. (E) Criss-cross in vitro suppression assay: sorted conventional tam-
iCD4TR2 and WT T cells were cocultured with sorted tam-iCD4TR2 and
wt Treg cells at various ratios. Analysis was performed after 96 h
(representative data of two independent experiments). (F) Develop-
ment of colitis in Rag12/2 mice after adoptive transfer of conventional
tam-iCD4TR2 and wt T cells alone or in combination with tam-iCD4TR2
Treg cells. Change in body weight after 8 wk posttransfer (mean 6 SEM,
3 mice per group, representative data of two independent experi-
ments).
doi:10.1371/journal.pbio.1001674.g008
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through induced deletion of TR2 in mature T helper cells only by
use of a novel CD4-CreERt2 system. It allowed induced
recombination of the TR2 target allele within up to 95% of
postthymic CD4+ T cells. Recombination during thymic develop-
ment remained small after short-term tamoxifen application, and
we did not find a contribution of TR2-deficient CD8+ T cells to
the peripheral T cell pool in this setup. Even long-term treatment
with tamoxifen resulted in recombination in only a small fraction
of CD8+ T cells. Only in one experimental setup, when thymic
development was initiated in the presence of tamoxifen, did we
observe a higher recombination frequency in CD8+ T cells.
Therefore, our CD4-CreERt2 system proved to be useful for the
study of TR2 function in peripheral CD4+ T cells. The reason for
the small recombination rate in DP thymocytes may lie in the fact
that the cells reside only shortly at this stage. Also, during this stage
expression of CreERt2 is initiated and protein has to first
accumulate. Therefore only a small number of DP cells is
receptive and exposed to tamoxifen at the same time. Further, only
a minor fraction of T cells is generated newly during the 5-d
treatment setup and can thus contribute to the peripheral pool.
Another factor influencing efficiency of Cre-mediated recombina-
tion is the accessibility of the target allele. Thus the extent of
recombination in the thymus may depend on the target used as
well as duration and route of tamoxifen application.
Taken together by using the tam-iCD4TR2 mouse for the
analysis of TGF-b’s role for CD4+ T cells, we report (i) the absence
of clinical or immunological manifestations of autoimmunity, even
when removal of TR2 from CD4+ T cells was maintained for
months; (ii) the development of a lethal autoimmune syndrome
only when TR2 ablation is induced during thymic development;
(iii) an increase in Tem and Treg proliferation as a result of
increased TCR signal sensitivity in the absence of TR2; and (iv)
that TGF-b signalling is not required for the maintenance of the
suppressive capacity of mature Treg cells in vitro and in vivo. We
therefore propose that the widely held notion of TGF-b signalling
being a major contributor to peripheral T cell tolerance and Treg
cell maintenance results from observations of developmental
aberrations due to the use of complete gene ablation during
thymic development under lymphopenic conditions.
Since the autoimmune syndrome in the most drastic cases of
TGF-b signal manipulation results in lethality at a very young age,
we hypothesized that neonatal lymphopenia was a contributing
factor. To distinguish between effects through mere lymphopenia
and aberration in thymic development, we performed TR2
ablation in three different lymphopenic setups, but all of them
failed to drive systemic autoinflammation. One condition,
adoptive transfer of TR2-deficient T cells into a lymphopenic
host, resulted solely in colitis, similar to a recently published study
of dLck-Cre–driven TR2 ablation [15]. We could show that the
difference between development of colitis (CD4-CreERt2/TR2f/f,
dLck-Cre/TR2f/f) and a lethal systemic autoimmune syndrome
(our thymic deletion model, CD4-Cre/TR2f/f, Lck-Cre/TR1f/f)
lies in whether TGF-b signalling is disrupted later than or at the
DP thymic stage, respectively. By use of the acute lymphopenia
models of sublethal irradiation and anti-CD4 depleting antibody
treatment, we focused on systems which were shown to drive T cell
proliferation by increased availability of IL-7, a setting which
amplifies signals from weak TCR/self-pMHC contacts [36,37].
We again observed hyperproliferation and basically complete
conversion to a (post)activated phenotype (unpublished data), yet
neither organ-specific nor systemic autoimmunity developed. A
difference in recombination frequencies could have been another
cause of the difference in development of autoimmunity between
the inducible and cell-type–specific systems, but we and others
[10,11] provided evidence to rule out this possibility. The decrease
of Treg cell numbers or of their suppressive activity in the
constitutive models are also an unlikely cause for development of
autoimmunity since activated TR2-deficient T cells in these
models were shown to be resistant to control by even WT Treg cells
[10,11,27]. Taken together, minor differences in gene deletion
efficiency as well as the presence/absence of Treg cells cannot
account for the divergent autoimmune phenotypes of the
constitutive and our inducible model. Also, impaired thymic
negative selection was ruled out by a study that found actually a
slight increase of negative selection in absence of TR2 [12].
Another possibility was that TR2 was not ablated in the T cell
subset required for development of autoimmunity, but several
studies indicated that both CD4+ and CD8+ T cells are responsible
for the autoimmune phenotype in absence of TGF-b signalling
[10,38,39]. We excluded this possibility by depletion of CD8+ T
cells in the setup. This resulted also in lethal autoimmunity, albeit
slightly delayed, and did not prevent weight loss and infiltration
into the lung and liver. Further, a recent study showed that TR2-
deficient CD4+ T cells alone can induce autoimmune colitis under
lymphopenic conditions [15], an observation that we confirmed in
our model. One report placed the pathogenic activity of TR2-
deficient T cells in unconventional NK T cells [10], but we show
that NK1.1 expression is not a mandatory characteristic of such
autoreactive T cells. Taken together, the only common denom-
inator for development of severe lethal autoimmunity upon
removal of TGF-b signalling in T cells is that recombination
must occur in developing thymocytes in a severely lymphopenic
animal. While a recent study reported that also the abrogation of
TGF-b signalling in CD11c+ cells leads to the development of
autoimmune disease [40], this seems unlikely in our system since
recombination in CD4+ CD11c+ cells was very rare.
When we used our model to analyze the role of TGF-b
signalling for survival and homeostasis of peripheral CD4+ T cells,
it revealed a modest increase in size of the Tem and Treg
compartments with both populations being activated (CD69+) and
cycling (BrdU+). For Tem cells such an effect has also been
reported when TGF-b signalling was abrogated by CD4-Cre or
through a CD4 promoter-driven dominant-negative TR2 trans-
gene, but the extent was far stronger than in our model [5,10,11].
In all such models the hyperproliferation and activation in CD8+
T cells was considerably larger than in CD4+ T cell compartment
[5,10,11].
As reported before [8,10,11] this hyperproliferation of TGF-b
unresponsive T cells depends on specific peptide-MHC recogni-
tion. The introduction of a TCR transgene, whose antigen is not
recognized in the periphery [41], into our model resulted in
amelioration of the proliferative phenotype (unpublished data).
This is supported by data from dLck-Cre–mediated TR2 ablation,
acting in late thymic development. In this model combination with
OT-I TCR transgene showed increased TCR sensitivity when
peptides of different affinities were used [15]. Similarly, we also
found increased sensitivity to TCR stimulation in vitro in the
absence of TR2, which may be a result of increased steady-state
intracytoplasmic calcium concentrations and faster calcium
response. Taken together, in all models of abrogation of TGF-b
signalling in T cells the threshold of productive TCR signalling is
decreased.
Even though we and Zhang and Bevan showed that increased
sensitivity of TCR signalling is a major factor in the increased
proliferative phenotype of TR2-deficient T cells, also direct
control of cell cycle by TGF-b signalling has been reported [42–
45]. Such cell-cycle control appears to be connected to the
establishment of T cell tolerance (anergy) in the DO11.10 model,
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thus again highlighting the importance of TGF-b in maintaining T
cell homeostasis [45].
As an additional cause of hyperproliferation and activation of
TGF-b unresponsive T cells, dysregulated sensitivity to cc
cytokines has been reported. The homeostasis especially of
CD8+ memory T cells was shown to be under IL-15 control,
possibly due to higher expression of CD122 in comparison to
CD4+ memory T cells (for rev: [37,46]). In agreement with this, a
CD2 promoter-driven dominant-negative TR2 transgene was
found to present with a IL-15–dependent expansion of memory-
like CD8+ T cells [8]. The T-bet–mediated up-regulation of
CD122 in CD4-Cre TR2 model, however, was observed in both
CD4+ and CD8+ T cells and was considered to be central for
maintenance and expansion of TGF-b–unresponsive memory T
cells [11]. In our inducible model we found neither evidence of
increased IL-2 production by activated CD4+ T cells nor increased
expression of CD25 (IL-2 Ra). We observed, however, a slight
increase in CD122 expression (IL2Rb chain) upon induced
ablation of TR2 in CD4+ T cells. Yet this did not lead to
increased sensitivity to common gamma chain cytokines, making
them an unlikely cause of the hyperproliferation seen in Tem and
Treg cells. Thus, the impairment of TGF-b signalling in peripheral
T cells leads to hyperproliferation independent of cytokine
signalling, while constitutive ablation during thymic development
results in dysregulated cc cytokine production/signalling and
massive autoimmunity.
We therefore conclude that TGF-b controls postthymic
homeostasis of both naı¨ve and memory CD4+ T cells. Yet the
extent of hyperproliferation in induced TR2-deficient T cells is
significantly lower than in constitutive TR2 mutants.
Previously, the almost complete absence of peripheral Treg cells
in CD4-Cre/TR2f/f animals was taken as evidence for a
prominent role of TGF-b in Treg cell maintenance [11]. In this
model Treg cells and precursors also showed a hyperproliferative
phenotype [11], but in the periphery Treg cells died prematurely
[12]. Also, the drastic expansion of thymic Treg cells in TR1-
deficient thymocytes [14] resulted in their failure to survive in the
periphery. In contrast to these observations, upon peripheral TR2
ablation Treg cells show increased proliferation without associated
collapse through massive apoptosis. This expansion of TR2-
negative Treg cells in peripheral lymphoid organ in our model was
restricted to Nrp-1+ Foxp3+ Treg cells, most likely cells of thymic
origin [23]. A specific increase of nTreg cells upon TR2 ablation is
also supported by the increase in number of Helios+ Treg cells [47].
Conversely and similar to our observation, TGF-b1 gene ablation
from activated peripheral T cells resulted in an expansion of Treg
cells [48], possibly a consequence of decreased local TGF-b
availability. Expansion of Treg cells could have been the result of
IL-2 production by the increased number of activated T cells in
tam-iCD4TR2 animals, but our data excluded this possibility.
Also, only mutant Treg cells showed increased cycling in mixed
bone marrow chimeras, thus ruling out any effects in trans. The
up-regulation of CD69 by Treg cells and in vitro stimulation with
suboptimal anti-CD3 concentrations suggest increased TCR
sensitivity, similar to conventional T cells.
We are to our knowledge the first to study Treg cell physiology
after induced peripheral abrogation of TGF-b signalling in vivo.
Our finding of the TGF-b independence of the mature,
postthymic Treg phenotype and function does agree with
epigenetic imprinting taking place at the Foxp3 locus and also
many other loci relevant for Treg cell physiology [49]. Upon
induced TR2 ablation we observed neither reduction of Foxp3,
CTLA-4, and GITR levels nor any decrease in the suppressive
capacity of TR2-deficient Treg cells. Tone and colleagues [50]
showed that TGF-b–induced Smad-mediated activation of the
Foxp3 locus through interaction with a conserved Smad-NFAT
response element (CNS1) in thymocytes is essential for nTreg cell
generation. Once the Treg phenotype is established, expression of
FoxP3 in nTreg cells is largely independent of the promoter region
CNS1 [51,52], which is supported by our observation of
unchanged FoxP3 levels. Further, Miyao and colleagues recently
showed that Treg cells represent a stable lineage, which robustly
maintains its committed state once the Treg cell-specific demeth-
ylation region (TSDR) has been demethylated [53].
TGF-b receptor signalling is, however, required for the
induction of Foxp3 among peripheral naı¨ve CD4+ T cells (iTregs)
[54,55]. In agreement with this, we found that in the lamina
propria, where iTreg cells contribute substantially to the Treg pool,
no Treg expansion can be observed upon induced TR2 ablation.
Finally, we could show that the proliferation of TR2-deficient
effector cells can be inhibited by TR2-deficient Treg cells, a
question that has been raised recently [56]. Thus, we propose that
ablation of TGF-b signalling during thymic development leads to
intrathymic hyperproliferation of Treg cells, which then cannot
survive in the periphery. Conversely, when TR2 is removed from
already established peripheral Treg cells, these cells keep their Treg
cell characteristics and undergo increased proliferation.
Taken together, our study suggests that several misconceptions
about TGF-b function for mature T cells are the result of gene
ablation during T cell development. By restricting the genetic
defect (TR2-deficiency) to mature CD4+ T cells, we show that
TGF-b signalling is not essential for the suppression of autoim-
munity. Furthermore, it is not obligatory for the maintenance of a
functional Treg cell pool. Instead it is required for the homeostasis
of Treg and Tem cells by curbing TCR signalling and therefore
overt proliferative activity. In contrast, ablation of TGF-b
signalling during thymic development as well as during lympho-
penia may predispose for development of autoimmunity. Thus,
TGF-b1 remains a cytokine with critical function in the regulation
of T cells, yet its role in peripheral tolerance has been
overestimated.
Materials and Methods
Generation of the CD4-CreERt2 Allele
Targeting of the CreERT2 fusion gene to the CD4 locus was
achieved by replacing part of exon 2 including the start codon with
the targeting vector pBluescript CD4-Cre19ERT2 by homologous
recombination in the C57BL/6 derived ES cell line Bruce4.
Colonies were analyzed for homologous recombination events by
Southern blot analysis of HindIII digested genomic ES cell DNA.
Two positive clones were used for blastocyst injection. Probes were
amplified with: 39PROBE: AAC TGC ACC GTG ACC CTG
GAC CAG AAA AAG AA and GTA GGA GTG AAG GTC
AGA GAC CAG GAC AAT AG; and 59PROBE: CTT CAA ATA
ATT AAC AAA ACA ACA AAA CCC TT and AAA AAC CAA
AAC CAA CCC AAA CAA AAA ACA T.
Animal Maintenance and Experiments
Tgfbr2fl/fl [57] were kindly provided by U. Malipiero, and
ROSA-EYFP mice [58] were kindly provided by A. Diefenbach,
C57BL/6J (B6) mice were purchased from Charles River and
congenic C57BL/6-CD45.1 bred in-house. CD4-CreERt2, CD4-
Cre, RAGE, TGFbRIIfl/fl, B6, B6-CD45.1, Rag12/2, and
ROSA-EYFP mice were maintained in barrier and specific
pathogen-free facilities at the University of Zurich and Technical
University of Munich and handled in accordance with approved
protocols under permits of the cantonal veterinary office. Organs
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and sera of fas-deficient animals were provided by Bojan Polic
(Rijeka, Croatia).
For genotyping of CD4-CreERt2 mice, the following primers
were used: GCC AGC TCA TTC CTC CCA CTC, CAT GGG
ACT TTG GGC TTC TAG G and CCC AAC CAA CAA GAG
AGC TCA AG, amplifying wt (440 bp) and transgene (720 bp).
Genotyping of TR2 was performed according to [57].
If not stated otherwise all mice used for the experiment were at
the age of 6 to 10 wk.
For tamoxifen (Sigma) application, tamoxifen was dissolved in
100% ethanol to 1 g/ml, vortexed, and mixed with olive oil to a
final concentration of 100 mg/ml. The suspension was incubated
at 56uC for 15 min and sonicated for 20 min. iCD4TR2 mice
were force-fed with 5 mg tamoxifen per day for 5 consecutive
days. Day 7 after start of application is denoted 1 wk p.a. For long-
term treatment, mice were fed with tamoxifen citrate (Harlan) for
8 or 12 wk ad libitum.
For induction of lymphopenia, mice were irradiated with 550
rad or injected i.p. once with 10 mg GK1.5 anti-CD4.
For depletion of CD8+ T cells, mice were injected at day 15 and
17 post–bone marrow transplantation with 250 mg of anti-CD8
antibody (YTS 169.4 clone, BioXcell) followed by 100 mg every
week. Controls received the same amount of isotype control
antibody LTF.2 (rat IgG2b, BioXcell).
Bone marrow chimeras were generated by i.v. transfer of T cell–
depleted bone marrow cells (16107) into lethally irradiated (1,100
rad) Rag12/2 mice. Thymectomies were performed under
Ketamine/Xylazine anaesthesia according to published proce-
dures [59].
For in vivo proliferation analysis BrdU (80 mg/100 ml) was
added to drinking water and changed every second day for 7 d.
Intracellular staining with anti-BrdU antibody (eBioscience) and
Foxp3 Staining Buffer Set (eBioscience) followed by DNAse
(Invitrogen) treatment for 1 h in 37uC was performed. Samples
were analyzed by using FACS Canto II.
For the in vivo suppression assay, Rag12/2 mice were injected
intraperitonelly with 46105 conventional T cells (CD45.1+) alone
or in combination with 26105 regulatory T cells (CD45.2+). Mice
were weighed and assessed for clinical sings of colitis weekly and
were killed 9 wk after transfer. Colons were fixed in 4% formalin,
paraffin-cut, and stained with hematoxylin and eosin according to
standard procedures.
For adoptive transfer experiments, Rag2/2 mice were injected
intraperitonelly with 26106 purified T cells (T cell isolation kit,
Milteny). Mice were weighed, assessed for clinical symptoms of
colitis weekly, and killed 7 wk after transfer.
Flow Cytometric Analyses
For flow cytometry the following fluorochrome conjugated
antibodies were used: anti-CD3, anti-CD4 (L3T4), anti-CD8a (53-
6.7), anti-CD8b (YTS 156.7.7), anti-CD19, anti-CD25,
anti-CD44, anti-CD45, anti-CD45.1, anti-CD45.2, anti-
CD45RB, anti-CD49b, anti-CD62L, anti-CD69, anti-CD122,
anti-CD154, anti-GITR, anti-NK1.1, anti-CCR4, anti-CCR5,
anti-CCR6, anti-CCR7, anti-IL2, anti-Ki-67, anti-INF-c, anti-IL-
4 all from BD Biosciences, anti-TGF-bRII from R&D, anti-Ly6A/
E, anti-CD90.2 from BioLegend anti-Foxp3, and anti-BrdU from
eBiosciences from Cell Signalling Technology. Staining for Foxp3,
BrdU, and Ki67 was performed using Foxp3 Staining Buffer Set
(eBiosciences) according to the manufacturer’s protocol. For
intracellular cytokine staining, cells were stimulated for 4 to 6 h
with 50 ng/ml PMA and 500 ng/ml Ionomycin and 1 ml/ml
GolgiPlug (BD Bioscience). Samples were acquired using FACS
CantoII (BD Biosciences) and analyzed with FlowJo software
(Treestar).
To enrich CD4+ T cells, population magnetic sorting was
performed (CD4 T cell isolation kit, Milteney Biotech) according
to the manufacturer’s protocol.
Treg cells and Tconv cells were sorted on a FACS Aria (BD
Biosciences) on the basis of being CD4+CD45RBloCD25+ and
CD4+CD45RBhiCD252, respectively. Naı¨ve CD4 T cells were
sorted on the basis of being CD4+CD44loCD62lhi, effector
memory/experienced CD4+CD44hiCD62llo, and central memory
CD4+CD44hiCD62lhi. For proliferation assays naı¨ve and memory
CD4+CD252 T cells were sorted.
Measurement of TCR Signalling
For calcium analysis, lymph node cells were labelled with Indo-
1 AM (1.5 mM, Invitrogen) for 45 min in 37uC, washed with 2%
FCS RPMI medium, and subsequently labelled with anti-CD8,
anti-CD19, anti-NK1.1, and anti-CD11b antibodies for 20 min in
4uC. Cells were resuspendet in 2% FCS RPMI, surface-labelled
with anti-CD3 (10 mg/ml final, eBioscience), and anti-CD28
antibody (10 mg/ml final, eBioscience) for 10 min on ice followed
by 10 min at 37uC. After addition of propidium iodide, a 15 s
baseline was acquired followed by TCR activation through
crosslinking with anti-hamster antibody (24 mg/ml final, Jackson
ImmunoResearch Laboratories). Samples were acquired using
LSR Fortessa (BD Biosciences) and analysed by FlowJo software
(Tristar).
Histological Tissue Analyses
Mice were euthanized with CO2, perfused first with PBS, and
then 4% paraformaldehyde in PBS. For histological analysis,
kidney, liver, heart, colon, and small intestine were fixed in 4%
paraformaldehyde in PBS, paraffin-embeded, cut into 30 mm thick
sections, and stained with hematoxylin-eosin and anti-CD3
antibody according to standard procedures.
In Vitro Proliferation Assay
Cells from the spleen or lymph nodes were cultured in RPMI
1640 (Invitrogen) medium supplemented with 10% FCS, 1%
penicillin-streptomycin, 0.5% 2-mercaptoethanol, stimulated for
72 h with different concentrations of anti-CD3 (2C11, BioXcell)
alone or together with 5 mg/ml anti-CD28 (N37, BioXCell).
For CFSE labelling, cells were first stained for 20 min in the
dark at room temperature with CFSE (carboxyfluorescein
diacetate succinimidyl diester, 5 mM) and washed in PBS. For
thymidine incorporation assays, 1 mCi of thymidin per well was
added for the last 24 h of cultures. For blocking of IL-2
signalling, the anti-CD25 antibody (PC61, eBioscience) at
different concentrations was added to the culture together with
anti-CD3 antibody. For assessment of the role of common c-
chain cytokine on proliferation, IL-2 and IL-15 (Peprotech)
were added to the culture at different concentrations together
with anti-CD3.
In Vitro Suppression Assay
The 56104 sorted conventional T cells and Treg cells (in ratios
according to figure legend) were cultured for 96 h in round-
bottomed plates along with anti-CD3 antibody (2C11, 2 mg/ml)
and irradiated splenocytes in RPMI 1640 medium supplemented
with 10% FCS, 1% penicillin-streptomycin, and 0.5% 2-mercap-
toethanol. T cell proliferation was determined by thymidine
incorporation and CFSE labelling of Tconv cells as described
above.
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In Vitro Apoptosis Assays
Lymphocytes from LN and spleens were stained for CD4,
CD44, CD62L, CD25, CD45RB, and sorted by using FACS Aria.
The purity for each population was above 95%. Cells were
cultured in AIM-V medium (Invitrogen) supplemented with
0.05% 2-mercaptoethanol (Sigma) without stimulation. After 20
and 40 h, staining for Annexin V (BD Bioscience) and Topro3 or
propidium iodide (1 mg/ml) was performed.
Quantitative Real-Time PCR Analysis
Different subsets of CD4 T cells were isolated by FACS sorting
and used for mRNA extraction (RNeasy mini kit, Qiagen). mRNA
was transcribed with M-MLV reverse transcriptase (Invitrogen).
Quantitative RT-PCR was performed with MyIQ cycler (Biorad)
using SyberGreen (Invitrogen). The following primers were used:
TR2: AAC GAC TTG ACC TGT TGC CTG T and CTT CCG
GGG CCA TGT ATC TT; and T-bet: CAA CAA CCC CTT
TGC CAA AG and TCC CCC AAG CAG TTG ACA GT. The
expression of the genes was standardized to the relative quantity of
RNA polymerase 2 detected by the primers CTG GTC CTT
CGA ATC CGC ATC and GCT CGA TAC CCT GCA GGG
TCA and normalized to the value of the respective control
condition.
Enzyme-Linked Immunosorbant Analysis (ELISA)
For detection of anti-dsDNA antibodies from the serum, ELISA
plates (BD Falcon) were pretreated with 0.1% poly-L-lysine
(Sigma) for 2 h, coated with 100 mg/ml DNA (Sigma) overnight,
and blocked with 2% BSA for 2 h. After washing with PBS, anti-
mouse IgG c chain HPR-conjugated antibody (Sigma) was applied
for 45 min and developed with stabilised chromogen (Invitrogen).
Immunoblotting
To analyze Smad2 phosphorylation MACS sorted CD4+ T cells
from tam-iCD4TR2 and control mice were stimulated with
20 ng/ml TGF-b1 (Peprotech). Western blot analysis was
performed after cell lysate separation in 10% SDS-PAGE gels
with anti-pSmad2 (Cell Signaling Technology) and a donkey anti-
rabbit Ig-G HRP secondary antibody.
Immunofluorescent Staining
NIH3T3 cells were cultured on poly-d-lysine (Sigma) precoated
glass slides. Cells were fixed with methanol (Fluka) for 10 min and
permeabilized with 1% Triton X-100 (Sigma) for 20 min. After
blocking with 10% normal goat serum (Dako), cells were
incubated overnight with serum diluted 1:200 in 1% goat serum
and 0.2% Triton X-100 (Sigma). Cells were incubated with goat
anti-mouse IgG antibody AlexaFluor 546 conjugated (Invitrogen)
for 45 min, and the nuclei were counterstained with Hoechst
33342 (Invitrogen). Analysis was performed on Olympus IX81
microscope with CellM software.
Statistics
The p values were calculated with Student’s t test using Prism
software. The p values of less than 0.05 were considered
significant. Where no p value is indicated through stars, no
statistically significant difference was found.
Supporting Information
Figure S1 Targeting strategy of the CD4-CreERt2
mouse. (A) Schematic map of the targeting strategy for the
CD4 Locus. The Cre-ERT2 open reading frame and an
FRT-flanked neomycin resistance gene were inserted into exon
2 of the CD4 locus of murine ES cells. HindIII restriction sites
used for Southern blot analysis of the targeted ES cell are
indicated. (B) Southern blot screen of the targeted ES cells after
digestion with HindIII and hybridization with the 59 external
probe and 39 external probes. Homologous recombination is
indicated by newly appearing 2.9 kb and 8.8 kb bands for the
targeted allele in addition to the 10.6 kb band for the WT allele.
(TIF)
Figure S2 Deletion efficiency of TR2 in the thymus and
spleen. (A) Flow cytometric analysis of TR2 expression by splenic
CD4+ and CD8+ T cells (left panel). Flow cytometric analysis of
TR2 expression by splenic effector memory, naı¨ve and CD25hi
CD4+ T cells (right panel). These are representative data of three
independent experiments. (B) Quantitative RT-PCR of TR2
mRNA in FACS-sorted thymocytes subsets 1 and 2 wk p.a. These
data are representative results of two independent experiments.
(TIF)
Figure S3 Schemes of experimental setups and FACS
analysis of TR2 deletion in respective experimental
setups. (A) The scheme of the experiment described in
Figure 3A–G. (B) The scheme of the experiment described in
Figure 3H. Flow cytometric analysis of TR2 expression by CD4+
and CD8+ T cells from peripheral blood after long-term tamoxifen
citrate treatment. (C) The scheme of the experiment described in
Figure 3J–K. Flow cytometric analysis of CD4+ and CD8+ T cell
frequencies in the spleen of chimeric mice at day 55 following anti-
CD8a (YTS 169.4) or isotype control treatment.
(TIF)
Figure S4 Schemes of experimental setups and FACS
analysis of TR2 deletion in lymphopenic environment.
(A) Scheme of the experiment described in Figure 4A and flow
cytometric analysis of TR2 expression by CD4+ and CD8+ T cells
from peripheral blood after long-term tamoxifen citrate treatment
(day 90). (B) Scheme of the experiment described in Figure 4C. (C)
The percentage and number of CD4+ T cells (left panel) and CD8+
T cells (right panel) in the mesenteric lymph nodes of Rag2/2 mice
7 wk after adoptive transfer of tam-iCDTR2 and control T cells
(mean 6 SEM, 5 mice per group, analysed in two independent
experiments).
(TIF)
Figure S5 Proliferation of TR2-deficient CD4+ T cells.
(A) Sorted effector memory and naı¨ve CD4+CD252 T cells were
cultured for 72 h and stimulated with indicated concentrations of
anti-CD3 antibody. Thymidine was added for the last 24 h of
culture (mean 6 SEM, 4 mice per group, analysed in two
independent experiments). (B) Proliferation analysis of sorted
CD4+ T cells cultured for 72 h with anti-CD3 (0.6 mg/ml) and
anti-CD25 (PC61) or with indicated cytokines. Thymidine was
added for the last 24 h of culture. (C) In vitro analysis of apoptosis
induction. Tam-iCD4TR2 and control cells were cultured in
AIM-V medium with or without tamoxifen. The ratio between
AnnexinV positive CD4+ T cells that were tamoxifen-treated
versus untreated is indicated (mean, 3 mice per group). These data
are representative of three independent experiments.
(TIF)
Figure S6 Foxp3 and Helios expression by TR2-defi-
cient regulatory T cells. (A) Flow cytometric analysis of the
expression of Foxp3 and CD25 by CD4+ T cells isolated from LN
at 2 wk p.a. (B) Flow cytometric analysis of the BrdU positive Treg
cells in experimental and control chimeras 2 wk p.a. (C) Flow
cytometric analysis of the expression of Helios and Foxp3 by CD4+
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T cells isolated from LN at 2 wk p.a. These are representative
results of two independent experiments. (D) Flow cytometric
analysis of CD69 expression by splenic Treg cells isolated from
tam-iCD4TR2 and control mice from indicated experimental
setups. (E) Proliferation analysis of Treg cells in vitro. Splenocytes
isolated from tami-CD4TR2 and control mice 2 wk p.a. were
labelled with CFSE and cultured for 72 h with indicated
concentrations of anti-CD3 antibody. Each row represents
proliferation of Treg cells from a different mouse. These are
representative data of two independent experiments.
(TIF)
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